LAG3 and neoplasm: Besides PD-1/PD-L1, CTLA-4, antibodies against three promising inhibitory receptors, LAG3, TIM-3, and TIGIT expressed on tumor-infiltrating lymphocytes (TILs) are under intense clinical development [6].